Compare Direxion Daily S&P 500 Bull 3X Shares (SPXL) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily S&P 500 Bull 3X Shares vs 10X Genomics Inc — how do they compare? Direxion Daily S&P 500 Bull 3X Shares trades at $297.97 (market cap $7.36B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: 10X Genomics Inc is the larger of the two by market cap, and Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily S&P 500 Bull 3X Shares for 32 Days and 10X Genomics Inc for 91 Days on average.
| SPXL | TXG | |
|---|---|---|
Market Cap | $7.36B | $10.07B |
Volume | 1,835,467 | 5,657,286 |
Sector | Leveraged / Inverse | Health |
52-Week High | $301.38 | $97.74 |
52-Week Low | $170.20 | $11.48 |
Typical Hold Time | 32 Days | 91 Days |
Enterprise Value | — | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPXL, a leveraged ETF tracking the S&P 500, trades at $293.05, down 1.28% on the day. Technical indicators show a bullish trend with strong moving average support, though oscillators remain neutral. The ETF reflects broader market sentiment where S&P 500 earnings are expected to grow 35% in 2026 (24/7 Wall Street, 2026-10-03), yet concerns about profit growth slowing to 15% in 2027 and high concentration in top holdings create uncertainty.
The outlook for SPXL is tied to S&P 500 performance, with Wall Street projecting a 21% rise to 9,275 by September 2027 (The Motley Fool, 2026-09-30). Key risks include market volatility, geopolitical tensions, and slowing earnings growth. Opportunities lie in seasonal bullish trends and AI-driven corporate spending, but leveraged exposure amplifies both gains and losses.
10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.
The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
